期刊文献+

卡维地洛治疗病毒性心肌炎机制的研究进展 被引量:4

Mechanism of carvedilol in treatment of viral myocarditis
下载PDF
导出
摘要 病毒性心肌炎发病机制仍不完全明确,治疗方法还在探索中。卡维地洛是一种新型的第三代β受体阻滞剂,具有β受体和α受体双重阻滞、调节细胞因子、抗氧化、抗心脏重构和抗心律失常等多方面的作用,通过减轻心肌炎症、延缓并逆转心室重构、改善血流动力学,从而减轻病毒性心肌炎病理生理改变,改善预后。目前关于卡维地洛治疗或干预病毒性心肌炎的报道日益增多,已逐渐受到重视。本文拟对卡维地洛治疗病毒性心肌炎机制的研究进展作一综述。 Carvedilol, a third-generation IS-blocker, can inhibit 15-receptor and or-receptor, regulate cytokine, has antioxidant, antiremodelling and antiarrhythmia ations and so on. It can attenuate inflammation, inhibit remodeling, improve hemodynamics and ameliorate prognosis of viral myocarditis. Now there have been more and more reports on the therapy of viral myocarditis with carvedilol. This article gives a review of research advances in mechanism of carvedilol in treatment of viral myocarditis.
出处 《国际药学研究杂志》 CAS 2007年第6期425-428,共4页 Journal of International Pharmaceutical Research
关键词 卡维地洛 心肌炎 心室重构 carvedilol myocarditis rentricular remodeling
  • 相关文献

参考文献19

  • 1[1]Nishio R,Shioi T,Sasayama S,et al.Carvedilol increases the production of interleukin-12 and interferon-γand improves the survival of mice infected with the encephalomyocarditis virus[J].J Am Coll Cardiol,2003,41(2):340-45.
  • 2[2]Molenaar P,Christ T,Ravens U,et al.Carvedilol blocks β2-more than β1-adrenoceptors in human heart[J].Cardiovasc Res,2006,69(1):128-39.
  • 3[3]Pauschinger M,Rutschow S,Chandrasekharan K,et al.Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis association with reduced myocardial interleukin-1beta and MMP-8 expression and a modulated immune response[J].Eur J Heart Fail,2005,7(4):444-52.
  • 4[4]Tschope C,Westermann D,Steendijk P,et al.Hemodynamic characterization of left ventricular function in experimental coxsackieviral myocarditis:effects of carvedilol and metoprolol[J].Eur J Pharmacol,2004,491(2/3):173-79.
  • 5李彬,廖玉华,黄艳霞,王敏,郭和平,李明慧,王秋芬.卡维地洛对87例充血性心力衰竭病人血浆细胞因子的影响[J].中国新药与临床杂志,2004,23(10):664-666. 被引量:3
  • 6[6]Calabrese F,Carturan E,Chimenti C,et al.Overexpression of tumor necrosis factor (TNF)alpha and TNFalpha receptor Ⅰin human viral myocarditis:clinicopathologic correlations[J].Mod Pathol,2004,17(9):1108-118.
  • 7[7]Li B,Liao YH,Cheng X,et al.Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction[J].Int J Cardiol,2006,111(2):247-55.
  • 8[8]Yuan Z,Shioji K,Kihara Y,et al.Cardioprotective effects of carvedilol on acute autoimmune myocarditis:anti-inflammatory effects associated with antioxidant property[J].Am J Physiol Heart Circ Physiol,2004,286(1):H83-90.
  • 9[9]Hirasawa K,Kim A,Han HS,et al.Effect of p38 mitogen-activated protein kinase on the replication of encephalomyocarditis virus[J].J Virol,2003,77(10):5649-656.
  • 10[10]Spallarossa P,Altieri P,Garibaldi S,et al.Matrix metalloproteinase-2 and-9 are induced differently by doxorubicin in H9c2 cells:the role of MAP kinase and NAD(P)H oxidase[J].Cardiovasc Res,2006,69(3):736-45.

二级参考文献23

  • 1Morgan T, Aubert JF, Brunner H. Interaction between sodium intake,angiotensin Ⅱ, and blood pressure as a couse of cardiac hypertrophy [J]. Am J Hypertens,2001,14(9 Pt1):914.
  • 2Xiao L, Pimental DR, Amin JK, et al. MEK1/2-ERK1/2 mediates α1-adrenergic receptor- stimulated hypertrophy in adult rat ventricular myocytes[ J ]. J Mol Cell Cardiol , 2001,33(4 ): 779.
  • 3Dahlof B, Zanchetti A, Diez J, et al. Effeets oflosartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy[J]. J Hypertens,2002,20(9): 1855.
  • 4Sack MN, Harrington LS, Jonassen AK, et al. Coordinate regulation of metabolic enzyme encoding genes during cardiac development and following carvedilol therapy in spontaneously hypertensive rats[ J]. Cardiovasc Drugs Ther,2000,14(1) :31.
  • 5Azevedo ER, Kubo T, Mar S, et al. Nonselective versus selective B-adrenergic receptor blockade in congestive heart failure[ J ]. Circulation, 2001,104(18) :2194.
  • 6Sung CP, Arleth AJ, Eichman C, et al. Carvedilol, a multiple-action neurohumoral antagonist, inhibits mitogen-activated protein kinase and cell cycle progression in vascular smooth muscle cells[J]. J Pharmacol Exp Ther,1997,283(2) :910.
  • 7Morisco C,Zebrowski D, Condorelli G, et al. The akt-glycogen synthase kinase 3 pathway regulates transcription of atrial natriuretic factor induced by-adrenergic receptor stimulation in cardiac myocytes[J]. J Biol Cardio , 2000 , 27 5 (19) : 14466.
  • 8Yamazaki T, Komuro I, Zou Y, et al. Norepinephrine induces the raf1 kinase/mitogen-activated protein kinase cascade through both α1and β-adrenoceptors[ J]. Circulation, 1997,95(5): 1260.
  • 9Berry C, Touyz R, Dominiczak AL, et al. Angiotensin receptors:signaling, vascular pathophysiology, and interactions with ceramide [ J ].Am J Physiol Heart Circ Physiol,2001,281(6) :2337.
  • 10Wei C, Cardarelli MG, Downing SW, et al. The effect of angiotensin Ⅱ on mitogen-activated protein kinase in human cardiomyocytes[ J].J Renin Angiotensin Aldosterone Syst ,2000,1(4) :379.

共引文献7

同被引文献81

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部